Application of Alvelestat in preparation of medicine for treating cerebral hemorrhage

By using Alvelestat to inhibit neutrophil elastase, the problem of lack of effective intervention for secondary damage in the treatment of cerebral hemorrhage in existing technologies has been solved. It has achieved the effects of reducing cerebral edema, promoting hematoma absorption and improving neurological function, and is suitable for pre-hospital emergency treatment and long-term rehabilitation of cerebral hemorrhage.

CN122163604APending Publication Date: 2026-06-09BEIJING TIANTAN HOSPITAL AFFILIATED TO CAPITAL MEDICAL UNIV
4 Cites 0 Cited by

Patent Information

Application Number
CN202610589477.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-04-30
Publication Date
2026-06-09

AI Technical Summary

Technical Problem

Current technologies lack effective strategies to block secondary brain injury in the treatment of cerebral hemorrhage, especially direct intervention in key initiation steps such as early recruitment, adhesion and migration of neutrophils. Furthermore, existing NE inhibitors such as cevelexat are not effective enough and have limited routes of administration.

Method used

Alvelestat, a highly selective inhibitor of neutrophil elastase, was administered orally or intraperitoneally to intervene in the activity of neutrophil elastase, inhibit inflammatory and immune-related signaling pathways, reduce cerebral edema, promote hematoma absorption, reduce neuronal apoptosis, and improve neurological functional outcomes.

Benefits of technology

It significantly reduces cerebral edema after cerebral hemorrhage, promotes hematoma absorption, reduces neuronal apoptosis, improves neurological function, and regulates multiple inflammatory and immune-related signaling pathways, providing a novel treatment strategy for cerebral hemorrhage that is suitable for pre-hospital emergency care and long-term rehabilitation.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention discloses an application of Alvelestat in preparation of a medicine for treating cerebral hemorrhage. On the basis of proteome layering analysis of hematoma fluid of a cerebral hemorrhage patient, neutrophil elastase (NE) is found to be a key molecule of cerebral hemorrhage progress, and then a technical scheme which takes NE as a target spot and adopts a selective NE inhibitor Alvelestat for intervention is provided. Animal experiments verify that the Alvelestat can relieve encephaledema, promote hematoma absorption, reduce neuronal apoptosis and improve neurological impairment; transcriptomics reveals that the compound plays a protection role by inhibiting a plurality of inflammatory immune related signal channels. The invention provides a new precise targeted treatment strategy for cerebral hemorrhage, and has a definite clinical transformation value.
Need to check novelty before this filing date? Find Prior Art